Trial · NCT02498652
Results by group95
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 95
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment A1 | -40.2 | Standard Error 3.29 | Maximum Percentage (%) Change | |
| Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment A2q | -55.0 | Standard Error 4.96 | Maximum Percentage (%) Change | |
| Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment A2b | -56.8 | Standard Error 4.52 | Maximum Percentage (%) Change | |
| Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment R1 | -48.1 | Standard Error 2.91 | Maximum Percentage (%) Change | |
| Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment R3 | -61.0 | Standard Error 2.59 | Maximum Percentage (%) Change | |
| Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment R5 | -69.5 | Standard Error 2.09 | Maximum Percentage (%) Change | |
| Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol. | Treatment A1 | 5.8 | Standard Error 0.24 | mg/dL | |
| Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol. | Treatment A2q | 4.8 | Standard Error 0.38 | mg/dL | |
| Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol. | Treatment A2b | 4.0 | Standard Error 0.39 | mg/dL | |
| Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol. | Treatment R1 | 5.5 | Standard Error 0.24 | mg/dL | |
| Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol. | Treatment R3 | 4.6 | Standard Error 0.22 | mg/dL | |
| Cohort 1 - Concentration of Serum Urate at 24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol. | Treatment R5 | 3.8 | Standard Error 0.18 | mg/dL | |
| Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%)) | Treatment A1 | 1065 | Standard Error 138 | Percentage (%) Change | |
| Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%)) | Treatment A2q | 1827 | Standard Error 252 | Percentage (%) Change | |
| Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%)) | Treatment A2b | 2633 | Standard Error 255 | Percentage (%) Change | |
| Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%)) | Treatment R1 | 899 | Standard Error 116 | Percentage (%) Change | |
| Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%)) | Treatment R3 | 958 | Standard Error 128 | Percentage (%) Change | |
| Cohort 1 - Renal Xanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeXO, CB (%)) | Treatment R5 | 827 | Standard Error 106 | Percentage (%) Change | |
| Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%)) | Treatment A1 | 400 | Standard Error 74.6 | Percentage (%) Change | |
| Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%)) | Treatment A2q | 517 | Standard Error 106 | Percentage (%) Change |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02498652/results